The current UCSD CFAR is a component of the AID Research Institute, an Organized Research Unit in the University of California System. We propose to expand the CFAR into a regional, comprehensive AIDS Research Center, with participating members drawn from UCSD and neighboring institutions including the Salk Institute, Scripps Research Foundation, the Burnham Cancer Research Foundation, and the La Jolla Institute for Allergy and Immunology. Dr. Flossie Wong-Staal and Dr. Douglas Richman will continue to serve as the Director and Co-director of the new Center. Their cooperation and complementary areas of expertise should strengthen the interaction of basic and clinical AIDS research as well as ensuring a continuation in leadership. The central mission of the new CFAR is to develop improved vaccines and therapies for HIV infection and associated disease through: (i) Basic Research in the areas of molecular pathogenesis and immunopathogenesis of HIV infection; (ii) Utilization of insights from basic research to develop pre-clinical and clinical trials of therapies and vaccines; (iii) Further clinical research to address fundamental scientific and practical medical issues; (iv) Providing leadership and serving as a regional resource to coordinate, stimulate and cross- fertilize all of the above to foster synergism, economies of scale and novel and creative approaches. The new CFAR will have a greatly strengthened Administrative Core to effectively coordinate the diverse activities of the Center. The Developmental Core will also be expanded in accordance with the growth in participating membership from neighboring institutions. A number of new cores will be established to keep pace with current needs and research activities on HIV. The proposed cores include five basic sciences cores: Molecular Biology, Virology, Flow Cytometry, Gene Therapy and Signal Transduction/Apoptosis and four clinical cores: Clinical Data and Outcomes, Clinical Investigation, Behavioral and Health Function and Primary Isolation and Specimen Banking. In addition, we will have access to a number of core facilities at different sites that are not directly funded by CFAR. A set of policies and procedures has been established to evaluate the performance of each core and to guide decisions in funding reallocation.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI036214-08
Application #
6163696
Study Section
Special Emphasis Panel (ZAI1-SCO-A (J1))
Program Officer
Plaeger, Susan F
Project Start
1994-04-01
Project End
2002-05-31
Budget Start
2000-03-01
Budget End
2002-05-31
Support Year
8
Fiscal Year
2000
Total Cost
$1,036,824
Indirect Cost
Name
University of California San Diego
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093
Fraser, Hannah; Mukandavire, Christinah; Martin, Natasha K et al. (2018) Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland. Addiction 113:2118-2131
Macal, Monica; Jo, Yeara; Dallari, Simone et al. (2018) Self-Renewal and Toll-like Receptor Signaling Sustain Exhausted Plasmacytoid Dendritic Cells during Chronic Viral Infection. Immunity 48:730-744.e5
Prakash, Katya; Gianella, Sara; Dubé, Karine et al. (2018) Willingness to participate in HIV research at the end of life (EOL). PLoS One 13:e0199670
Wertheim, Joel O; Murrell, Ben; Mehta, Sanjay R et al. (2018) Growth of HIV-1 Molecular Transmission Clusters in New York City. J Infect Dis 218:1943-1953
Dubé, Karine; Luter, Stuart; Lesnar, Breanne et al. (2018) Use of 'eradication' in HIV cure-related research: a public health debate. BMC Public Health 18:245
Papasavvas, Emmanouil; Lada, Steven M; Joseph, Jocelin et al. (2018) Analytical ART interruption does not irreversibly change pre-interruption levels of cellular HIV. AIDS :
Dubé, Karine; Gianella, Sara; Concha-Garcia, Susan et al. (2018) Ethical considerations for HIV cure-related research at the end of life. BMC Med Ethics 19:83
Chaillon, Antoine; Gianella, Sara; Lada, Steven M et al. (2018) Size, Composition, and Evolution of HIV DNA Populations during Early Antiretroviral Therapy and Intensification with Maraviroc. J Virol 92:
Bengtson, Angela M; Pence, Brian W; Eaton, Ellen F et al. (2018) Patterns of efavirenz use as first-line antiretroviral therapy in the United States: 1999-2015. Antivir Ther 23:363-372
Basova, Liana; Najera, Julia A; Bortell, Nikki et al. (2018) Dopamine and its receptors play a role in the modulation of CCR5 expression in innate immune cells following exposure to Methamphetamine: Implications to HIV infection. PLoS One 13:e0199861

Showing the most recent 10 out of 921 publications